Stay updated on Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The page has been updated to include a new section on HHS Vulnerability Disclosure and has been revised to version 2.16.8, indicating a potential enhancement in security or compliance. The previous version reference has been removed.
    Difference
    1%
    Check dated 2025-07-25T15:22:18.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The page has updated its content to include new information on the safety and activity of an anti-PD-L1 antibody in advanced cancer patients, while removing previous references to pembrolizumab for non-small-cell lung cancer.
    Difference
    9%
    Check dated 2025-07-18T12:08:00.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    A service alert has been added regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.
    Difference
    1.0%
    Check dated 2025-07-11T07:34:01.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.
    Difference
    1%
    Check dated 2025-07-04T04:25:22.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The page has removed a reference to a study on the safety and activity of an anti-PD-L1 antibody in patients with advanced cancer.
    Difference
    0.6%
    Check dated 2025-06-27T00:48:23.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been pushed back from June 2025 to July 2025.
    Difference
    0.9%
    Check dated 2025-06-19T20:09:55.000Z thumbnail image

Stay in the know with updates to Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.